by Jill Svete | Sep 13, 2023 | Newsletters
By Bill Frack, Chief Product Officer Another benefit renewal season is almost complete, and many employers have been told that – barring action – their second largest fixed expense will be increasing by 7%+. The actuaries are expecting inflation to flow through...
by Jill Svete | Aug 17, 2023 | Newsletters
By Bill Frack, Chief Product Officer Situation The journey to treat cancer is arduous, complicated, and expensive. Cancer care is the highest spend category for high-cost claimants in many employers’ health plans. Effective cancer care is a function of three key...
by boomer | Aug 2, 2023 | Newsletters
Situation The journey to treat cancer is arduous, complicated and expensive. Cancer care is the highest spend category for high-cost claimants in many employers’ health plans. Effective cancer care is a function of three key variables: Timely discovery – early stage...
by boomer | Jun 15, 2023 | Newsletters
By Jake Steepleton, Rx Product Specialist Situation Spending on GLP-1 drugs which treat Type 2 diabetes and obesity has surged. Weekly prescriptions for OZEMPIC® soared 111% between Feb 2022 to Feb 2023, making it the costliest drug for many employers, surpassing...
by mike | Jun 15, 2023 | Newsletters
By Bill Frack, Chief Product Officer and Mike Maley, Head of Product Situation The journey to treat cancer is arduous, complicated and expensive. Cancer care is the leading category of cost for high-cost claimants in many employers’ health plans. Effective cancer care...
by mike | May 16, 2023 | Newsletters
Situation Who doesn’t love a good discount? There’s a reason why rebates have been around for over a century! Just as with common consumer goods, the pharmacy benefit manager model with up to 30% rebates appeals to our sense of shopping savvy. Through RFP processes,...
